However, there is a growing body of evidence that after tumors are established, IL-17A has protumorigenic functions, because IL-17A has been shown to be produced by breast cancer tumor-infiltrating lymphocytes and thereby to promote chemoresistance, proliferation, and migration of breast cancer cells [38]. This evidence concerns the gene IL17A and breast carcinoma.